Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomaximaFRA:944 +0.20%60 EV-to-EBITDA is 11.97 as of Sep. 01, 2026, which is 3% below its 10-year median of 12.39. GuruFocus rates FRA:944 with a GF Score™ of 60/100 and a GF Value™ of €2.93. The stock has 4 warning signs investors should review. Among 121 Medical Diagnostics & Research companies, Biomaxima ranks better than 61.98% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biomaxima's enterprise value is €13.39 Mil.
Biomaxima's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €1.12 Mil. Therefore, Biomaxima's EV-to-EBITDA for today is 11.97.
The historical rank and industry rank for Biomaxima's EV-to-EBITDA or its related term are showing as below:
FRA:944'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.88 Med: 12.39 Max: 81.41
Current: 12.15
During the past 13 years, the highest EV-to-EBITDA of Biomaxima was 81.41. The lowest was -9.88. And the median was 12.39.
FRA:944's EV-to-EBITDA is ranked better than 61.98% of 121
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.24
vs FRA:944: 12.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biomaxima's share price for today is €1.978.
Biomaxima's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Biomaxima's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:944 vs TMO, DHR, NTRA: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Biomaxima's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomaxima EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomaxima's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biomaxima's EV-to-EBITDA falls into.
Biomaxima's current Enterprise Value is €13.39 Mil.
Biomaxima's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomaxima (FRA:944) has a EV-to-EBITDA of 11.97 as of Sep. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biomaxima. This is near median its historical median of 12.39. According to the industry distribution chart, Biomaxima ranks #46 out of 121 companies in the Medical Diagnostics & Research industry, placing it in the top 38%.
Is Biomaxima's EV-to-EBITDA too high?
Biomaxima's current EV-to-EBITDA of 11.97 is near median its 10-year median of 12.39. The Medical Diagnostics & Research industry median EV-to-EBITDA is 16.24. Biomaxima's value of 11.97 is 26.3% below this industry median. Based on the distribution chart, Biomaxima ranks #46 out of 121 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Biomaxima has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Biomaxima's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomaxima ranks #46 out of 121 companies for EV-to-EBITDA. This puts Biomaxima in the upper half of its industry. The industry median EV-to-EBITDA is 16.24. Biomaxima's value of 11.97 is 26.3% below this benchmark. While the company's 10-year median is 12.39 vs. the industry median of 16.24, Biomaxima has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.24, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomaxima's current EV-to-EBITDA of 11.97 is 26.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biomaxima. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomaxima's current EV-to-EBITDA is 11.97, which is near median its own 10-year median of 12.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomaxima stock overvalued right now?
Biomaxima (FRA:944) has a current EV-to-EBITDA of 11.97. The stock's GF Value™ is €2.93, compared to a current price of €1.98 — trading 32.5% below its estimated fair value. The current EV-to-EBITDA is 11.97, which is near median its 10-year median of 12.39 and 26.3% below the Medical Diagnostics & Research industry median of 16.24. Biomaxima's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Biomaxima (FRA:944), the current EV-to-EBITDA is 11.97 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomaxima (FRA:944) Overvalued in 2026?
Based on GuruFocus' analysis, Biomaxima stock appears to be undervalued.
The current stock price of €1.98 is trading 32.5% below its estimated GF Value™ of €2.93.
Key valuation signals for FRA:944:
EV-to-EBITDA: 11.97 (near median its 10-year median of 12.39)
GF Value™: €2.93 vs. price of €1.98 (32.5% below fair value)
Industry Position: 26.3% below the Medical Diagnostics & Research median (#46 of 121)
No single metric tells the full story. See the FRA:944 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
60GF Score
Get the complete analysis for FRA:944
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:944 has been successfully added to your 
